Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparability of Orforglipron Capsules in Healthy Participants
NCT06692348Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of orforglipron in obesity and type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoints: Steady-state Area Under the Concentration Versus Time Curve of Orforglipron (Fasted State), Steady-state Maximum Concentration of Orforglipron (Fasted State) and 2 more. Started Dec 2024; status: completed.
02
Drugs
orforglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06692348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692348.